AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04702750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (odors)
Description: I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
Study NCT04702750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (sounds)
Description: I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
Study NCT05746884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duodenal mucosectomy
Description: Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
Study NCT05746884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duodenal mucosectomy
Description: Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
Study NCT05746884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ampullectomy
Description: Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
Study NCT05746884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ampullectomy
Description: Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
Study NCT05576207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced energy and protein supplement for pregnant women
Description: A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
Study NCT05576207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Micronutrient Supplement for pregnant women
Description: Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group.
Study NCT06250257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine mesylate plus standard GDMT
Description: The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
Study NCT06250257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate plus standard GDMT
Description: The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
Study NCT06222424 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: outpatient prescription issues
Description: Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
Study NCT05815784 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atropine
Description: 0.05% atropine. One drop per eye per day for 2 years.
Study NCT06745076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT06745076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT06745076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT06745076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06745076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT06745076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study NCT06745076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Complete questionnaire
Study NCT04551066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered QD orally
Study NCT04551066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally
Study NCT04551066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally
Study NCT04551066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study NCT06326489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switching to the Medtronic 780G insulin pump
Description: Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
Study NCT01430429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0801
Study NCT05320627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Eligible patients will receive Edoxaban tablet once a day for 12 weeks
Study NCT05054244 — intervention group
Intervention type: OTHER
Intervention: standard wound treatment
Description: Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
Study NCT05054244 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperbaric oxygenation (HBOT)
Description: The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
Study NCT05523518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Buzzy®
Description: From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
Study NCT05523518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AccuVein®
Description: In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
Study NCT04146298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered prior to cell infusion.
Study NCT04146298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered prior to cell infusion.
Study NCT04146298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mutant KRAS G12V-specific TCR transduced autologous T cells
Description: After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
Study NCT04146298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
Study NCT05322590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
Study NCT05322590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
Study NCT05815784 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MiSight contact lenses
Description: Daily wear for 2 years.
Study NCT05269940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: oral dosing, once daily
Study NCT06024330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VAN assessment
Description: An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
Study NCT06024330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VES assessment
Description: An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
Study NCT06024330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LARIO assessment
Description: An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
Study NCT06442774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS).
Study NCT06442774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring via wearable
Description: Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
Study NCT06442774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring via wearable
Description: Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
Study NCT06361745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD19 chimeric antigen receptor
Description: Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
Study NCT06617793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion
Study NCT06617715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV13
Description: One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
Study NCT06617715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: One dose of Prevnar® (0.5 mL) is administered intramuscularly.
Study NCT04461509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer
Study NCT06681077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Community Health Education
Description: Receive I CAN intervention
Study NCT06681077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05138848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in Bed Restriction
Description: Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.
Study NCT05138848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Schedule
Description: Participants will maintain their typical sleep schedule for 4-weeks.
Study NCT05649124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
Study NCT05138848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Schedule
Description: Participants will maintain their typical sleep schedule for 4-weeks.
Study NCT06618417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sleep apnea home-evaluation
Description: Participants will receive a home-monitoring device by mail to test for sleep apnea at home
Study NCT06676189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with medial pivot polyethylene
Description: total knee arthroplasty with medial pivot polyethylene
Study NCT06676189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with ultra-congruent polyethylene
Description: total knee arthroplasty with ultra-congruent polyethylene
Study NCT06623331 — intervention group
Intervention type: OTHER
Intervention: AI-enhanced endoscopy training
Description: Endoscopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.
Study NCT06623331 — intervention group
Intervention type: OTHER
Intervention: Conventional endoscopy training
Description: Endoscopists trained conventionally
Study NCT06696391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Excess Ultrasound (VEXUS)-Guided Management
Description: Expert operators will perform VEXUS within 6 hours of randomization and repeat the assessment every 24 hours for 3 days, or until ICU discharge or death. After each assessment, investigators will grade the severity of venous congestion using a modified version of the VEXUS score and provide updated management recommendations.~Patients without congestion will receive standard fluid management. For mild congestion, investigators will implement fluid restriction (e.g., minimizing maintenance fluids) while maintaining nutrition and blood product administration as clinically indicated. For moderate to severe congestion, investigators will 1. target negative fluid balance (-1 to -2L/24h) through fluid restriction and diuretics, 2. perform cardiac ultrasound to guide inotrope administration and optimize RV physiology, and 3. optimize PEEP for ventilated patients.~All patients will receive the standard of care based on Surviving Sepsis Campaign guidelines.
Study NCT06719089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable double loop ureteral stent
Description: This ureteral stent is based on natural polymers and degrades inside the human body without causing obstruction, avoiding the need of a second surgery for stent removal and minimizing complications related to encrustation and bacterial infections.
Study NCT06719089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PolyUrethane Double Loop Ureteral Stent
Description: This ureteral stent is a double J made of 100% polyurethan, heat-sensitive and radiopaque for excellent patient tolerance and high incrustation resistance.
Study NCT06779955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: foot massage application
Description: The characteristics of Massage Manipulations are an important feature in planning. Since the purpose of the massage is to rest, calm and relax, Effleurage (Stroke), Petrisage (Kneading) and Friction (Circular Rubbing) techniques that support circulation and have a loosening effect on the tissues have been chosen.A massage will be given to both feet for a total of 16 minutes, 8 minutes for each foot.The person receiving the massage will be lying down comfortably in a supine position, supported by pillows under the head and lower legs.Foot massage will be applied once to patients in the supine position at the first hour after their admission to the coronary intensive care unit following transfemoral angiography.
Study NCT06781268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Kinetic Training
Description: Combination of cognitive and physical exercises aimed at improving neuroplasticity, agility, balance, and cognitive functions.
Study NCT06780657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online hypopressive exercise training program
Description: The hypopressive exercises were based on recommendations from the literature and consultation with an expert in the field. Each session will be held twice a week for 20-25 minutes. Participants will perform each exercise 10 times during these sessions.
Study NCT06780748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Identification rate of sentinel lymph node
Description: To evaluate the identification rate of sentinel lymph nodes (SLNs). The study will compare the identification rates based on different localization techniques for SLN mapping
Study NCT06780241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: CMR (with contrast at baseline and non-contrast at follow-up)
Study NCT06780241 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
Study NCT06338059 — intervention group
Intervention type: OTHER
Intervention: Vitamin B12 Level
Description: Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
Study NCT06781060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Faradic Nerve Stimulation Therapy+Standard Physiotherapy
Description: This is electrical nerve stimulation with faradic type current to the injured nerve for conservative treatment of post injection sciatic nerve injury.
Study NCT05090150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home delivery of ART
Description: Home ART refill and monitoring, adherence support
Study NCT05090150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Lockers (Pele boxes)
Description: Decentralized ART refills and monitoring, adherence support
Study NCT05090150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices + conditional lottery incentives
Description: Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
Study NCT05090150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best clinic practices
Description: Continue with best clinic practices
Study NCT06171880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JLP-1901
Description: administration of JLP-1901
Study NCT06171880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1901
Description: administration of JLP-1901
Study NCT06171880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JC-001(active comparator)
Description: administration of JC-001(tenofovir)